XML 100 R68.htm IDEA: XBRL DOCUMENT v3.21.2
Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) $ 96.4 $ 63.0 $ (410.5) $ (57.5)
Income Tax Expense (Benefit) (409.1) 446.1 (364.9) 738.2
Product revenues 2,775.0 3,681.6 5,469.0 7,215.9
Net income attributable to Biogen Inc. 448.5 1,542.1 858.7 2,941.2
Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Net income attributable to Biogen Inc. (27.6) 27.7 (49.0) 42.5
Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) (0.4) 3.9 (0.9) (12.5)
Income Tax Expense (Benefit) 0.1 (0.8) 0.2 2.6
Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) (0.1) 0.1 0.1 0.2
Income Tax Expense (Benefit) 3.0 (0.1) 5.3 (0.2)
Product revenues 30.7 23.7 53.8 50.7
Operating Expenses 0.4 0.0 0.0 (0.1)
Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) $ 0.1 $ 0.9 $ 0.1 $ 1.8